Bremelanotide Nasal Spray For Female Sexual Dysfunction Shows Favorable Phase IIa Trial Results
Filed in archive Drugs, Vaccines and Therapeutics by ruth on August 3, 2006
in men, but Palatin Technologies, Inc. (AMEX: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) seems to be making headway with a nasal spray designed to treat female sexual arousal disorder (FSAD) in post-menopausal women. Phase IIapilot studies involving 26 patients diagnosed with FSAD showed favorable results.
Results showed that on a 14-item questionnaire, 73 percent of the women reported an increased level of genital arousal while on bremelanotide compared with 23 percent of women on placebo. Also, 46 percent of women on bremelanotide reported an increased level of sexual desire while only 19 percent of women responded similarly after placebo treatment. Additionally, subjects receiving bremelanotide reported a higher incidence of engaging in sexual activity compared to placebo.
Bremelanotide, the active ingredient in the nasal spray, is the first compound in a new drug class called melanocortin receptor agonists under development to treat sexual dysfunction.The companies are now enrolling patients for an larger Phase IIb trials throughout the US.
Permalink: Bremelanotide Nasal Spray For Female Sexual Dysfunction Shows Favorable Phase IIa Trial Results
Tags:
sexual
menopause
biotech
phase
bremelanotide
sexual+dysfunction
trial+results
female+sexual
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/31022
Mr Wong
| 
